Skip to content
    Real-World Studies

    Frequency and Duration of Clinically Relevant TKI and PPI Interactions in Cancer Patients

    van Elp et alBasic & Clinical Pharmacology & Toxicology

    Proton pump inhibitors (PPIs) elevate gastric pH, which reduces the oral bioavailability of numerous tyrosine kinase inhibitors (TKIs) and can compromise oncologic efficacy. In a retrospective observational study evaluating real-world prescription patterns from the Dutch IADB.nl database between January 1, 2013, and December 31, 2024, investigators assessed the prevalence and duration of clinically relevant TKI-PPI drug-drug interactions (DDIs). DDIs were identified across four pharmacology compendia: KNMP Kennisbank, Health Base, Lexidrug, and Merative Micromedex, with concomitant use defined as at least 7 days of overlapping prescriptions.
    Among 60 TKIs registered in the Netherlands, 19 were flagged by at least one compendium for clinically relevant interactions with PPIs. Clinically significant DDIs occurred in 22.3% of TKI recipients (393 of 1,759 patients). Overlapping therapy extended for a median of 43 days (interquartile range = 81 days), and 91.1% of these co-prescription episodes persisted for 30 days or longer. Given the widespread and sustained co-prescription of PPIs and TKIs in oncology practice, clinicians should exercise heightened vigilance and adapt dosing regimens or gastroprotective strategies to avoid attenuating TKI therapeutic response.

    Key Takeaways

    • Among 1,759 cancer patients treated with tyrosine kinase inhibitors, 22.3% (393 patients) received a concomitantly prescribed proton pump inhibitor resulting in a clinically relevant drug-drug interaction.
    • Concomitant TKI and PPI exposure had a median duration of 43 days (IQR = 81), with 91.1% of co-prescription episodes lasting at least 30 days.
    • Of 60 tyrosine kinase inhibitors registered in the Netherlands, 19 had clinically relevant interactions with proton pump inhibitors documented in at least one evaluated drug compendium.
    Read the original sourceBasic & Clinical Pharmacology & Toxicology